DCM
FHTX icon

Driehaus Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Driehaus Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-568,470
Closed -$3.27M – 409
2024
Q2 		$3.27M Buy
568,470
+288,088
+103% +$1.72M 0.03% 276
2024
Q1 		$1.88M Sell
280,382
-63,338
-18% -$352K 0.02% 308
2023
Q4 		$2.22M Hold
343,720
– – 0.03% 293
2023
Q3 		$1.72M Hold
343,720
– – 0.02% 310
2023
Q2 		$2.42M Hold
343,720
– – 0.03% 294
2023
Q1 		$2.13M Buy
343,720
+13,669
+4% +$89.5K 0.03% 316
2022
Q4 		$2.11M Hold
330,051
– – 0.03% 291
2022
Q3 		$2.83M Sell
330,051
-52,889
-14% -$681K 0.04% 295
2022
Q2 		$5.21M Buy
382,940
+62,940
+20% +$812K 0.08% 270
2022
Q1 		$4.87M Buy
320,000
+230,000
+256% +$3.16M 0.06% 303
2021
Q4 		$2.06M Buy
+90,000
New +$1.29M 0.02% 302

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Driehaus Capital Management's FHTX Position: Q3 2024 in Review

Driehaus Capital Management sold out of Foghorn Therapeutics (FHTX) in Q3 2024, closing a stake of 568,470 shares — an estimated $3.27M sold.

Driehaus Capital Management first reported a position in FHTX in Q4 2021 and held it in 11 quarters. The position peaked at $5.21M in Q2 2022. 79 funds tracked by Wall St. Rank hold FHTX as of Q3 2024.

  • Driehaus Capital Management reported no remaining Foghorn Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Driehaus Capital Management sold 568,470 Foghorn Therapeutics shares in Q3 2024, an estimated $3.27M.
  • Driehaus Capital Management first reported a position in Foghorn Therapeutics in Q4 2021 and held it in 11 quarters.
  • Driehaus Capital Management's Foghorn Therapeutics position peaked at $5.21M in Q2 2022.
  • 79 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2024.

Based on Driehaus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.